U.S. markets open in 1 hour 29 minutes

iShares iBoxx $ High Yield Corporate Bond ETF (HYG)

NYSEArca - NYSEArca Delayed Price. Currency in USD
Add to watchlist
86.97-0.13 (-0.15%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close87.10
Bid86.69 x 2200
Ask87.66 x 39400
Day's Range86.93 - 87.16
52 Week Range67.52 - 87.79
Avg. Volume27,863,013
Net Assets25.72B
PE Ratio (TTM)N/A
YTD Daily Total Return0.67%
Beta (5Y Monthly)0.55
Expense Ratio (net)0.49%
Inception Date2007-04-04
  • ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

    ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the following investor conferences in March: H.C. Wainwright Global Life Sciences Conference – On-demand pre-recorded company overview available on March 9, 2021 at 7:00 a.m. ET / 4:00 a.m. PT; and Oppenheimer 31st Annual Healthcare Conference – Presenting company overview on March 16, 2021 at 2:30 p.m. ET / 11:30 a.m. PT. Webcasts of each presentation will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the events. About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials in combination with (1) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors and (2) Xtandi (enzalutamide) in metastatic prostate cancer. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com. Investor Contact:Dominic Piscitelli, Chief Financial Officerdominic.piscitelli@oricpharma.cominfo@oricpharma.com

  • ETF.com

    Feb. 2021 ETF Inflows Second Largest Ever

    Investors added $88.7 billion to U.S.-listed ETFs during February.

  • ETF.com

    Spiking Yields Pierce Bonds & Growth Stocks

    Interest rates hit their highest levels in a year on Wednesday, putting pressure on long-duration assets.